Abstract
To determine the effect of systemic thrombolysis with low-dose recombinant tissue plasminogen activator (rtPA) and the body-weight adjusted platelet GPIIb/IIIa receptor antagonist tirofiban, the authors performed lesion volumetry on magnetic resonance perfusion and diffusion images recorded before thrombolysis and on T2-weighted magnetic resonance images on day 8. Treatment with rtPA and tirofiban (n = 13) resulted in a 50% lesion reduction (p < 0.03), while lesion reduction was less in rtPA treatment (n = 16) and absent in nontreated patients (n = 18).
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anticoagulants / therapeutic use
-
Brain / pathology
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / etiology
-
Brain Ischemia / pathology
-
Drug Synergism
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Heparin / therapeutic use
-
Humans
-
Image Processing, Computer-Assisted
-
Infarction, Middle Cerebral Artery / complications
-
Infarction, Middle Cerebral Artery / drug therapy*
-
Infarction, Middle Cerebral Artery / pathology
-
Magnesium / therapeutic use
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Prospective Studies
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / therapeutic use
-
Thrombolytic Therapy*
-
Tirofiban
-
Tissue Plasminogen Activator / administration & dosage
-
Tissue Plasminogen Activator / therapeutic use*
-
Treatment Outcome
-
Tyrosine / administration & dosage
-
Tyrosine / analogs & derivatives*
-
Tyrosine / therapeutic use*
Substances
-
Anticoagulants
-
Recombinant Proteins
-
Tyrosine
-
Heparin
-
Tissue Plasminogen Activator
-
Tirofiban
-
Magnesium